Retatrutide Reconstitution & Dosing: A Research Handling Guide
Quick Answer: Reconstituting Retatrutide
Retatrutide (LY3437943) ships as a lyophilised (freeze-dried) powder that must be reconstituted into solution with bacteriostatic water before it can be measured and used in the laboratory. The single most important number is the concentration, and it follows one simple rule: concentration (mg/ml) = milligrams of peptide in the vial ÷ millilitres of water added.
So a 10 mg vial reconstituted with 2 ml of bacteriostatic water yields a 5 mg/ml solution. Add 1 ml instead and you get 10 mg/ml; add 5 ml and you get 2 mg/ml. The peptide quantity never changes - only how dilute it is, and therefore how much sits in each unit drawn on a syringe. Everything else in this guide builds on that one equation.
Below we cover the step-by-step reconstitution method, the mg-per-unit maths on a standard U-100 syringe, the dose-titration schedule used in the published Phase 2 trial, the compound's half-life and why it was dosed weekly, and the storage and stability points that matter once a vial is in solution.
Why Lyophilised Peptides Need Reconstituting
Peptides are fragile molecules. To survive shipping and storage they are freeze-dried into a stable solid - the small puck or film of powder you see at the bottom of the vial. In that dry state the molecule is far more stable than it would be in solution, which is why research peptides are supplied lyophilised rather than pre-mixed.
To work with the peptide you return it to a liquid by adding a sterile diluent. Bacteriostatic water is the standard choice: it is water for injection containing roughly 0.9% benzyl alcohol, a preservative that suppresses bacterial growth and allows a reconstituted vial to be entered multiple times over a period of weeks rather than being a single-use preparation. Plain sterile water and 0.9% sodium chloride are also used in some protocols, but bacteriostatic water is preferred for multi-draw research handling because of that preservative. Velox supplies it in 3 ml and 10 ml presentations.
Reconstitution does not change how much peptide you have - a 10 mg vial contains 10 mg of retatrutide whether you add 1 ml or 5 ml of water. What you are choosing when you pick a volume is the concentration, and through it, how finely you can measure each aliquot.
Step-by-Step Reconstitution
Working cleanly protects both the peptide and your results. The sequence used in most research protocols is:
1. Equilibrate. Let the sealed vial and the bacteriostatic water come to room temperature before opening - cold glass encourages condensation and makes the powder harder to judge.
2. Sanitise. Wipe both rubber stoppers with an alcohol swab and let them dry.
3. Draw the diluent. Draw your chosen volume of bacteriostatic water (for example 2 ml) into a sterile syringe.
4. Add slowly, down the wall. Inject the water gently against the inside glass wall of the vial, letting it run down onto the powder rather than blasting the powder directly. A fast jet onto the puck can shear the peptide.
5. Dissolve by swirling. Roll or swirl the vial gently until the solution is completely clear. Never shake - agitation foams the solution and can denature the molecule.
6. Label and store. Write the concentration and date on the vial and place it at 2–8 °C, protected from light.
A correctly reconstituted vial is clear and colourless. Cloudiness, visible particles, or a tint that does not clear with gentle swirling are reasons to set the vial aside rather than use it.
The Concentration Maths (mg Per Unit)
Research aliquots are usually measured on a U-100 insulin syringe, where the barrel is graduated in "units." The convention is simple: 100 units = 1 ml, so 1 unit = 0.01 ml. Combine that with your concentration and you know exactly how much peptide each unit holds:
Concentration (mg/ml) = peptide (mg) ÷ water added (ml)
Per unit (mg) = concentration (mg/ml) × 0.01
The table below shows how the reconstitution volume changes the per-unit amount for a 10 mg vial. A 20 mg vial behaves identically at double the concentration for the same volume.
| BAC water added | Concentration | Per unit (U-100) | Units for a 2 mg aliquot |
|---|---|---|---|
| 1.0 ml | 10 mg/ml | 0.10 mg (100 mcg) | 20 units (0.20 ml) |
| 2.0 ml | 5 mg/ml | 0.05 mg (50 mcg) | 40 units (0.40 ml) |
| 2.5 ml | 4 mg/ml | 0.04 mg (40 mcg) | 50 units (0.50 ml) |
| 4.0 ml | 2.5 mg/ml | 0.025 mg (25 mcg) | 80 units (0.80 ml) |
| 5.0 ml | 2 mg/ml | 0.02 mg (20 mcg) | 100 units (1.00 ml) |
Worked example
Reconstitute a 10 mg vial with 2 ml of bacteriostatic water → 5 mg/ml. To measure a 2 mg research aliquot, divide the target by the concentration: 2 mg ÷ 5 mg/ml = 0.4 ml = 40 units. Need a 4 mg aliquot from the same vial? 4 ÷ 5 = 0.8 ml = 80 units. The arithmetic is always target-amount divided by concentration, then multiplied by 100 to read it in units.
Prefer not to do the maths by hand? Our reconstitution calculator takes the vial size, the water volume and the target amount and returns the units to draw.
Dose Figures Reported in the Phase 2 Trial
The most-cited human data for retatrutide is the Phase 2 obesity trial published by Jastreboff and colleagues in the New England Journal of Medicine in 2023.[1] It is the standard reference researchers use to understand the dose range the compound was studied across. Participants received once-weekly subcutaneous maintenance doses of 1, 4, 8 or 12 mg, each reached gradually through a 4-weekly dose-escalation schedule rather than starting at the target dose. The escalation was used to manage tolerability.
So the 12 mg arm did not begin at 12 mg: it stepped up 2 → 4 → 8 → 12 mg in four-week increments, with the lower-target arms stopping at their assigned maintenance level. These figures describe how the molecule was studied in a controlled clinical trial - they are a literature reference point, not a protocol for human use, and they are reproduced here only so researchers can map published dose ranges onto the concentration maths above.
Half-Life: Why It Was Dosed Weekly
A compound's half-life is the time taken for its concentration to fall by half. The Phase 1 pharmacokinetic work by Urva and colleagues, published in The Lancet in 2022, reported a mean half-life for LY3437943 of approximately six days.[2] That long half-life is the property that supported a once-weekly dosing interval in the trials: with elimination spread over roughly six days, a weekly interval keeps exposure relatively smooth rather than spiking and crashing between doses.
One practical consequence of a multi-day half-life is accumulation: when a compound is dosed more frequently than it is fully cleared, each dose adds to the residue of the previous one until intake and elimination balance. This steady state is typically reached after roughly four to five half-lives - for retatrutide, on the order of several weeks. It is one of the reasons the trials escalated the dose slowly rather than introducing the full target dose immediately.
Storage & Stability After Reconstitution
Before reconstitution, lyophilised retatrutide is best held at 2–8 °C, desiccated and protected from light, where it is stable long-term; for extended storage many laboratories keep unopened vials frozen. After reconstitution, the solution should be refrigerated at 2–8 °C and protected from light. The benzyl alcohol in bacteriostatic water suppresses microbial growth, which is what allows a reconstituted vial to be drawn from across a multi-week working window rather than being single-use.
A few handling points preserve the peptide's integrity once it is in solution: avoid repeated freeze–thaw cycles of the reconstituted liquid, never shake the vial, keep it out of direct light, and return it to the fridge promptly after each draw. As with any research reagent, inspect the solution before each use and discard it if it has turned cloudy or developed particulates.
Common Reconstitution Mistakes
Shaking instead of swirling. Vigorous agitation foams the solution and can shear or denature the peptide. Always swirl gently.
Blasting the powder. Firing the diluent directly onto the puck rather than running it down the glass wall stresses the molecule. Add the water slowly against the side.
Forgetting to record the concentration. The same vial can be 10 mg/ml or 2 mg/ml depending on the water added - an unlabelled vial makes every later calculation a guess. Label concentration and date immediately.
Confusing units with millilitres. On a U-100 syringe, 1 unit is 0.01 ml, not 1 ml. Mixing the two up is the single most common arithmetic error.
Key Published Research
This randomised, double-blind, placebo-controlled Phase 2 trial studied retatrutide across once-weekly maintenance doses of 1, 4, 8 and 12 mg, reached via a 4-weekly dose-escalation schedule. It is the primary literature reference for the dose range over which the compound has been characterised in humans.
PMID: 37366315 - N Engl J Med. 2023;389(6):514–526
This Phase 1b study characterised the human pharmacokinetics of LY3437943, reporting a mean half-life of approximately six days with dose-proportional exposure - the property that supported a once-weekly dosing interval in later trials.
PMID: 36356631 - Lancet. 2022;400(10366):1869–1881
Velox Peptides Supply Information
Supplied as a research reagent only. Not a medicine. Not evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy.
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. PMID: 37366315
- Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a Phase 1b study. Lancet. 2022;400(10366):1869–1881. PMID: 36356631
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple GIP, GLP-1 and glucagon receptor agonist for glycemic control and weight loss. Cell Metab. 2022;34(6):882–898.e6. PMID: 35108511
Frequently Asked Questions
How do you reconstitute retatrutide?
Add bacteriostatic water to the lyophilised powder. Let the vial and water reach room temperature, sanitise the stoppers, draw your chosen volume of water (commonly 1–2 ml per 10 mg vial), inject it slowly down the inside wall of the vial, and swirl gently until clear. Concentration equals milligrams of peptide divided by millilitres of water added. For research handling only.
How much bacteriostatic water do you add to a 10 mg vial?
It is a research choice that sets the concentration. 1 ml gives 10 mg/ml; 2 ml gives 5 mg/ml; 5 ml gives 2 mg/ml. More water makes the solution more dilute, so each syringe unit holds less peptide. This is reconstitution maths, not human dosing guidance.
How many units is a given amount of retatrutide?
On a U-100 syringe, 1 unit = 0.01 ml. Divide the target amount by the concentration to get millilitres, then multiply by 100 for units. Example: from a 5 mg/ml solution, a 2 mg aliquot is 2 ÷ 5 = 0.4 ml = 40 units.
What is the half-life of retatrutide?
Human pharmacokinetic data (Urva et al., Lancet 2022) reported a mean half-life of approximately six days for LY3437943 - the property that supported once-weekly dosing in the clinical trials. Research observation only.
What doses were used in the retatrutide clinical trial?
The Phase 2 obesity trial (Jastreboff et al., NEJM 2023) used once-weekly maintenance doses of 1, 4, 8 and 12 mg, reached through a 4-weekly escalation (for the 12 mg arm: 2 → 4 → 8 → 12 mg). These describe the published trial design and are not instructions for human use.
Is retatrutide legal to buy in the UK for research?
Yes. Retatrutide is legal to purchase in the UK for in vitro research use only. It is not a licensed medicine and is not approved for human use. Velox Peptides supplies it strictly as a research reagent under our Research Use Policy.
